NO20081888L - Triazolforbindelser som lipoksygenaseinhibitorer - Google Patents

Triazolforbindelser som lipoksygenaseinhibitorer

Info

Publication number
NO20081888L
NO20081888L NO20081888A NO20081888A NO20081888L NO 20081888 L NO20081888 L NO 20081888L NO 20081888 A NO20081888 A NO 20081888A NO 20081888 A NO20081888 A NO 20081888A NO 20081888 L NO20081888 L NO 20081888L
Authority
NO
Norway
Prior art keywords
triazole compounds
lipoxygenase inhibitors
lipoxygenase
treatment
compounds
Prior art date
Application number
NO20081888A
Other languages
English (en)
Inventor
Benjamin Pelcman
Andrei Sanin
Peter Nilsson
Hasse Kromann
Original Assignee
Biolipox Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolipox Ab filed Critical Biolipox Ab
Publication of NO20081888L publication Critical patent/NO20081888L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Forbindelse med formelen I, der W er en valgfritt substituert aryl- eller heteroarylgruppe, og farmasøytisk akseptable salter av samme. Forbindelsene er egnet til behandling av sykdommer der inhibering av aktiviteten av et lipoksygenase (for eksempel 15-lipoksygenase) er ønskelig og/eller påkrevet, og særlig til behandling av inflammasjon.
NO20081888A 2005-10-31 2008-04-21 Triazolforbindelser som lipoksygenaseinhibitorer NO20081888L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73148105P 2005-10-31 2005-10-31
PCT/GB2006/004010 WO2007051982A1 (en) 2005-10-31 2006-10-27 Triazole compounds as lipoxygenase inhibitors

Publications (1)

Publication Number Publication Date
NO20081888L true NO20081888L (no) 2008-07-01

Family

ID=35810092

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081888A NO20081888L (no) 2005-10-31 2008-04-21 Triazolforbindelser som lipoksygenaseinhibitorer

Country Status (14)

Country Link
US (1) US20090186918A1 (no)
EP (1) EP1943234A1 (no)
JP (1) JP2009513691A (no)
KR (1) KR20080067364A (no)
CN (1) CN101300236A (no)
AU (1) AU2006310367A1 (no)
BR (1) BRPI0618079A2 (no)
CA (1) CA2627516A1 (no)
EA (1) EA200801108A1 (no)
IL (1) IL191061A0 (no)
NO (1) NO20081888L (no)
NZ (1) NZ567605A (no)
WO (1) WO2007051982A1 (no)
ZA (1) ZA200803636B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200800911A (en) * 2005-10-20 2008-01-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
TW200732320A (en) * 2005-10-31 2007-09-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
WO2007052000A1 (en) * 2005-11-01 2007-05-10 Biolipox Ab Pyrazoles useful in the treatment of inflammation
MX2009011816A (es) 2007-05-03 2009-11-19 Pfizer Ltd Derivados de piridina.
WO2011028651A1 (en) * 2009-09-01 2011-03-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of human 15-lipoxygenase-1
KR101810975B1 (ko) 2010-07-08 2017-12-20 에스케이바이오팜 주식회사 카바모일옥시 아릴알칸노일 아릴피페라진계 화합물을 포함하는 약학적 조성물
EP2616458B1 (en) * 2010-09-13 2016-07-20 Basf Se Pyridine compounds for controlling invertebrate pests ii
US20140031355A1 (en) 2010-11-04 2014-01-30 Amgen Inc. Heterocyclic compounds and their uses
JP2016501203A (ja) 2012-11-20 2016-01-18 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インドールアミン２，３−ジオキシゲナーゼの阻害剤として有用な化合物
KR101612179B1 (ko) * 2013-04-19 2016-04-12 영남대학교 산학협력단 아미도피리딘올 유도체 또는 이의 약제학적 허용가능한 염을 유효성분으로 함유하는 암질환 예방 또는 치료용 약학조성물
TW201623288A (zh) * 2014-05-14 2016-07-01 諾華公司 甲醯胺衍生物
EP3108883A1 (en) * 2015-06-22 2016-12-28 Fundació Institut de Recerca Biomèdica de Bellvitge Therapeutic uses of non-peptide inhibitors of the calcineurin - nfat signalling pathway
CN111057058B (zh) * 2020-01-03 2021-02-02 浙江工业大学 一种制备1H-[1,2,3]-三唑并[4,5-c]喹啉类化合物的方法
CN113466395B (zh) * 2021-08-03 2023-11-21 杭州微源检测技术有限公司 一种检测瑞戈非尼和中间体药物中4-氯-3-三氟甲基异氰酸苯酯含量的方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1306260C (en) * 1985-10-18 1992-08-11 Shionogi & Co., Ltd. Condensed imidazopyridine derivatives
US5258397A (en) * 1988-11-30 1993-11-02 Novapharme 3-Isoxazoyl derivatives endowed with anticonvulsant activity, procedure for their preparation and their pharmaceutical compositions
US5464860A (en) * 1988-11-30 1995-11-07 Novapharme N(pyrazol-3-yl) benzamides and pharmaceutical compositions
FR2639636B1 (fr) * 1988-11-30 1994-03-04 Novapharme Nouveaux composes heterocycliques a activite anticonvulsivante, procede de preparation et compositions therapeutiques les contenant
DE69329856D1 (de) * 1992-05-20 2001-02-15 Merck & Co Inc Ester derivate von 4-aza-steroiden
ATE195530T1 (de) * 1992-05-20 2000-09-15 Merck & Co Inc 17-ether und thioether von 4-aza-steroiden
US6372770B1 (en) * 1994-10-12 2002-04-16 Euro-Celtique, S.A. Benzoxazoles
US5663357A (en) * 1995-11-22 1997-09-02 Allergan Substituted heteroarylamides having retinoid-like biological activity
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
CA2373510A1 (en) * 1999-05-12 2000-11-23 Ortho-Mcneil Pharmaceutical, Inc. Pyrazole carboxamides useful for the treatment of obesity and other disorders
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
GB0002666D0 (en) * 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
CA2399791A1 (en) * 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
GB0011094D0 (en) * 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (III)
EP1319657A4 (en) * 2000-09-22 2005-03-02 Nihon Nohyaku Co Ltd N- (4-PYRAZOLYL AMIDE) DERIVATIVES, CHEMICALS FOR AGRICULTURAL AND HORTICULTURAL USE AND APPLICATIONS THEREOF
JP4465133B2 (ja) * 2001-02-08 2010-05-19 クミアイ化学工業株式会社 イソオキサゾリン誘導体及びこれを有効成分とする除草剤
DE10110750A1 (de) * 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
ATE455104T1 (de) * 2001-11-01 2010-01-15 Icagen Inc Pyrazolamide zur anwendung in der behandlung von schmerz
TWI263497B (en) * 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
WO2004039795A2 (en) * 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Amide compounds for the treatment of hyperlipidemia
ATE454378T1 (de) * 2002-11-01 2010-01-15 Vertex Pharma Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
US7382703B2 (en) * 2002-12-13 2008-06-03 Matsushita Electric Industrial Co., Ltd. Optical disc apparatus
US7429581B2 (en) * 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
SE0300705D0 (sv) * 2003-03-14 2003-03-14 Biolipox Ab New compounds
WO2004080999A1 (en) * 2003-03-14 2004-09-23 Biolipox Ab Pyrazole compounds useful in the treatment of inflammation
US7429603B2 (en) * 2003-04-25 2008-09-30 3-Dimensional Pharmaceuticals, Inc. C-fms kinase inhibitors
GB0312609D0 (en) * 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
EP1794130A1 (en) * 2004-09-20 2007-06-13 Biolipox AB Pyrazole compounds useful in the treatment of inflammation
TW200800911A (en) * 2005-10-20 2008-01-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
TW200732320A (en) * 2005-10-31 2007-09-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
WO2007052000A1 (en) * 2005-11-01 2007-05-10 Biolipox Ab Pyrazoles useful in the treatment of inflammation

Also Published As

Publication number Publication date
US20090186918A1 (en) 2009-07-23
WO2007051982A1 (en) 2007-05-10
ZA200803636B (en) 2009-10-28
EP1943234A1 (en) 2008-07-16
BRPI0618079A2 (pt) 2011-08-16
CN101300236A (zh) 2008-11-05
NZ567605A (en) 2010-07-30
JP2009513691A (ja) 2009-04-02
CA2627516A1 (en) 2007-05-10
AU2006310367A1 (en) 2007-05-10
IL191061A0 (en) 2008-12-29
EA200801108A1 (ru) 2008-10-30
KR20080067364A (ko) 2008-07-18

Similar Documents

Publication Publication Date Title
NO20081888L (no) Triazolforbindelser som lipoksygenaseinhibitorer
NO20081804L (no) Pyrazolforbindelser egnet til behandling av inflammasjon
NO20073416L (no) Indoler nyttig i behandlingen av inflammasjon
NO20092033L (no) Nye forbindelser
NO20071617L (no) Indozolonderivater som 11B-HSD1-inhibitorer
NO20091858L (no) Hydrobenzamid derivater som inhibitorer av HSP90
NO20061506L (no) Heterocykliske inhibitorer av MEK og fremgangsmater for anvendelse derav
NO20063647L (no) Nye inhibitorer av chymase
NO20090216L (no) Forbindelser med CRTH2 antagonistaktivitet
NO20050141L (no) Prodrugs av imidazolderivater for anvendelse som protonpumpeinhibitorer ved behandlingen av f.eks. peptisk ulcus
GEP20125537B (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
NO20054852L (no) GFAT inhibitorer
NO20081454L (no) Met-kinaseinhibitorer
NO20081846L (no) Bifenylderivater og deres anvendelse ved behandling av hepatitt C
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
NO20091590L (no) Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer
NO20043587L (no) Nye heterocykliske forbindelser som er aktive som inhibitorer av beta-laktamaser
EA200802329A1 (ru) Производные триазола ii
NO20083267L (no) Azaindole inhibitorer av aurora kinaser
NO20060670L (no) N3-substituerte imidazopyridin C-kit inhibitorer
NO20084912L (no) Bisykliske derivater som CETP-inhibitorer
EA201000098A1 (ru) Производные хиназолинамида
DE602005011452D1 (de) Zur behandlung von entzündungen geeignete indole
DE602005009209D1 (de) Zur behandlung von entzündungen geeignete indole
MX2012004089A (es) Inhibidores de hsp90.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application